2. Academic Validation
  3. Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone

Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone

  • Cell Death Dis. 2021 Sep 23;12(10):868. doi: 10.1038/s41419-021-04161-1.
Yunfei He  # 1,  Dongdong Cheng  # 2,  Cheng Lian 1,  Yingjie Liu 1,  Wenqian Luo 1,  Yuan Wang 1,  Chengxin Ma 1,  Qiuyao Wu 1,  Pu Tian 1,  Dasa He 1,  Zhenchang Jia 1,  Xianzhe Lv 1,  Xue Zhang 1,  Zhen Pan 2,  Jinxi Lu 3,  Yansen Xiao 1,  Peiyuan Zhang 1,  Yajun Liang 1,  Qingcheng Yang 4,  Guohong Hu 5 6
Affiliations

Affiliations

  • 1 CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
  • 2 Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
  • 3 Department of General Surgery, Xinzhou District People's Hospital, Wuhan, China.
  • 4 Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. [email protected].
  • 5 CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China. [email protected].
  • 6 Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. [email protected].
  • # Contributed equally.
PMID: 34556636 DOI: 10.1038/s41419-021-04161-1
Abstract

Giant cell tumor of bone (GCTB) is an aggressive osteolytic bone tumor characterized by the within-tumor presence of osteoclast-like multinucleated giant cells (MGCs), which are induced by the neoplastic stromal cells and lead to extensive bone destruction. However, the underlying mechanism of the pathological process of osteoclastogenesis in GCTB is poorly understood. Here we show that the proteoglycan Serglycin (SRGN) secreted by neoplastic stromal cells plays a crucial role in the formation of MGCs and tumorigenesis in GCTB. Upregulated SRGN expression and secretion are observed in GCTB tumor cells and patients. Stromal-derived SRGN promotes osteoclast differentiation from monocytes. SRGN knockdown in stromal cells inhibits tumor growth and bone destruction in a patient-derived orthotopic xenograft model of mice. Mechanistically SRGN interacts with CD44 on the cell surface of monocytes and thus activates focal adhesion kinase (FAK), leading to osteoclast differentiation. Importantly, blocking CD44 with a neutralizing antibody reduces the number of MGCs and suppresses tumorigenesis in vivo. Overall, our data reveal a mechanism of MGC induction in GCTB and support CD44-targeting approaches for GCTB treatment.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-12289
    99.87%, FAK Inhibitor
    FAK